New Therapies for Reducing Low-Density Lipoprotein Cholesterol

被引：28

作者：

Stein, Evan A. ^{[1
]}

Raal, Frederick J. ^{[2
]}

机构：

[1] Metab & Atherosclerosis Res Ctr, Cincinnati, OH 45227 USA

[2] Univ Witwatersrand, Fac Hlth Sci, Dept Med, ZA-2193 Johannesburg, South Africa

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2014年 / 43卷 / 04期

关键词：

LDL cholesterol; Apo B antisense; MTP inhibitors; PCSK9; inhibitors; SUBTILISIN/KEXIN TYPE 9; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; TRIGLYCERIDE TRANSFER PROTEIN; ESTER TRANSFER PROTEIN; CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; MONOCLONAL-ANTIBODY; LDL CHOLESTEROL; DOUBLE-BLIND;

D O I：

10.1016/j.ecl.2014.08.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although the past 4 decades have been the most productive in transitioning from an low-density lipoprotein cholesterol (LDL-C) hypothesis to demonstration of clinical benefit, cardiovascular disease remains a major cause of mortality and morbidity. It is fortunate that most of the effective lipid-lowering drugs, the statins, have become generic and inexpensive. However, there remains a large unmet medical need for new and effective agents that are also well tolerated and safe, especially for patients unable to either tolerate statins or achieve optimal LDL-C on current therapies. It is likely that the agents discussed in this review will fill that need.

引用

页码：1007 / +

页数：28

共 74 条

[1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].

Abifadel, M ;

Varret, M ;

Rabès, JP ;

Allard, D ;

Ouguerram, K ;

Devillers, M ;

Cruaud, C ;

Benjannet, S ;

Wickham, L ;

Erlich, D ;

Derré, A ;

Villéger, L ;

Farnier, M ;

Beucler, I ;

Bruckert, E ;

Chambaz, J ;

Chanu, B ;

Lecerf, JM ;

Luc, G ;

Moulin, P ;

Weissenbach, J ;

Prat, A ;

Krempf, M ;

Junien, C ;

Seidah, NG ;

Boileau, C .

NATURE GENETICS, 2003, 34 (02) :154-156

[2] Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia [J].

Akdim, Fatima ;

Visser, Maartje E. ;

Tribble, Diane L. ;

Baker, Brenda F. ;

Stroes, Erik S. G. ;

Yu, Rosie ;

Flaim, Joann D. ;

Su, John ;

Stein, Evan A. ;

Kastelein, John J. P. .

AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (10) :1413-1419

[3] 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult [J].

Anderson, Todd J. ;

Gregoire, Jean ;

Hegele, Robert A. ;

Couture, Patrick ;

Mancini, G. B. John ;

McPherson, Ruth ;

Francis, Gordon A. ;

Poirier, Paul ;

Lau, David C. ;

Grover, Steven ;

Genest, Jacques, Jr. ;

Carpentier, Andre C. ;

Dufour, Robert ;

Gupta, Milan ;

Ward, Richard ;

Leiter, Lawrence A. ;

Lonn, Eva ;

Ng, Dominic S. ;

Pearson, Glen J. ;

Yates, Gillian M. ;

Stone, James A. ;

Ur, Ehud .

CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (02) :151-167

[4]

[Anonymous], EUR HEART J

[5] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[6] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[7] Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels [J].

Berthold, Heiner K. ;

Seidah, Nabil G. ;

Benjannet, Suzanne ;

Gouni-Berthold, Ioanna .

PLOS ONE, 2013, 8 (03)

[8]

Billups Sarah J, 2005, J Manag Care Pharm, V11, P681

[9] A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia [J].

Blom, Dirk J. ;

Hala, Tomas ;

Bolognese, Michael ;

Lillestol, Michael J. ;

Toth, Phillip D. ;

Burgess, Lesley ;

Ceska, Richard ;

Roth, Eli ;

Koren, Michael J. ;

Ballantyne, Christie M. ;

Monsalvo, Maria Laura ;

Tsirtsonis, Kate ;

Kim, Jae B. ;

Scott, Rob ;

Wasserman, Scott M. ;

Stein, Evan A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (19) :1809-1819

[10] Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients [J].

Bloomfield, Daniel ;

Carlson, Gary L. ;

Sapre, Aditi ;

Tribble, Diane ;

McKenney, James M. ;

Littlejohn, Thomas W., III ;

Sisk, Christine McCrary ;

Mitchel, Yale ;

Pasternak, Richard C. .

AMERICAN HEART JOURNAL, 2009, 157 (02) :352-U20

← 1 2 3 4 5 6 7 8 →